Robert B. Kargbo, Ph.D.
Affiliations: | 2008 | North Dakota State University, Fargo, ND, United States |
Area:
Allylation, Medicinal ChemistryGoogle:
"Robert Kargbo"Mean distance: 8.51 | S | N | B | C | P |
Parents
Sign in to add mentorGregory R. Cook | grad student | 2008 | North Dakota State University | |
(Asymmetric addition of organoindium reagent to hydrazones.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Kargbo RB. (2020) RAF Kinases in Cancer: A Moving Target and Degradation Therapy. Acs Medicinal Chemistry Letters. 11: 1369-1370 |
Kargbo RB. (2020) Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1367-1368 |
Kargbo RB. (2020) PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease. Acs Medicinal Chemistry Letters. 11: 1092-1093 |
Kargbo RB. (2020) PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1090-1091 |
Kargbo RB. (2020) Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 412-413 |
Kargbo RB. (2020) BRM Targeting Compounds for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 99-100 |
Kargbo RB. (2019) PROTAC Degradation of Bromodomain for the Treatment of Hyperplasia and Cancer. Acs Medicinal Chemistry Letters. 10: 1372-1373 |
Kargbo RB. (2019) PROTAC Degradation of IRAK4 for the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1370-1371 |
Kargbo RB. (2019) PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1367-1369 |
Kargbo RB. (2019) PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers. Acs Medicinal Chemistry Letters. 10: 1102-1103 |